Individual biological variability influences how patients respond to ubiquitin proteasome drugs. Differences in protein turnover rates, stress tolerance, and cellular metabolism affect treatment outcomes.

Some cells are inherently more sensitive to proteasome disruption due to higher protein synthesis demands. Identifying these characteristics helps guide personalized therapy.

Biological profiling supports tailored dosing and treatment schedules, improving effectiveness while reducing unnecessary side effects.

Personalization aligns therapy with each patient’s cellular biology rather than a one-size-fits-all approach.